Intech Investment Management LLC Grows Stock Holdings in Insulet Corporation $PODD

Intech Investment Management LLC raised its holdings in Insulet Corporation (NASDAQ:PODD) by 1,592.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 48,869 shares of the medical instruments supplier’s stock after acquiring an additional 45,982 shares during the period. Intech Investment Management LLC’s holdings in Insulet were worth $15,087,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in PODD. Sage Mountain Advisors LLC increased its stake in Insulet by 4.6% in the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 33 shares during the last quarter. Curi Capital LLC grew its holdings in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares during the period. Evelyn Partners Investment Management Services Ltd grew its holdings in Insulet by 28.7% in the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after buying an additional 39 shares during the period. PDS Planning Inc lifted its holdings in shares of Insulet by 5.1% during the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock worth $253,000 after acquiring an additional 40 shares during the period. Finally, Camarda Financial Advisors LLC lifted its holdings in shares of Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after acquiring an additional 40 shares during the period.

Insider Activity at Insulet

In related news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.39% of the company’s stock.

Insulet Stock Performance

NASDAQ:PODD opened at $251.50 on Friday. The firm’s fifty day simple moving average is $269.07 and its 200 day simple moving average is $303.58. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The firm has a market capitalization of $17.71 billion, a price-to-earnings ratio of 71.86, a PEG ratio of 1.48 and a beta of 1.41.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.15 EPS. As a group, equities research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PODD. Royal Bank Of Canada boosted their target price on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a report on Friday, November 21st. UBS Group reissued a “buy” rating on shares of Insulet in a research note on Thursday, December 18th. Wolfe Research upped their price objective on Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. TD Cowen cut Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price on the stock. in a report on Monday, January 26th. Finally, Raymond James Financial lowered their price target on Insulet from $385.00 to $355.00 and set an “outperform” rating for the company in a research report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $354.57.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.